Gavi, the vaccine alliance, is utilizing lessons learned from the COVID-19 pandemic to respond swiftly to the ongoing mpox outbreak. Drawing from the $500 million First Response Fund, Gavi is providing Africa with 500,000 doses of the MVA-BN mpox vaccine, aiming to address the needs of the continent, though significant gaps in supply remain.
The Democratic Republic of Congo received its first shipment of mpox vaccines on Thursday, marking a significant step in combating the ongoing outbreak. This comes after the World Health Organization declared the mpox outbreaks in 12 African countries a global health emergency. The vaccines, donated by the European Union, are expected to help address the inequity in access to vaccines between African nations and wealthier countries.
Pakistan has reported its fifth mpox case, with Peshawar emerging as an epicenter for the virus. The recent case involves a traveler returning from the Gulf, raising concerns about the spread from West Asia. Authorities are implementing stringent screening measures at airports and coordinating closely to contain the outbreak.
A new, more transmissible and severe strain of mpox (Clade I) has emerged in Africa and is spreading globally, prompting authorities in Europe, China, and other countries to intensify screening efforts. The World Health Organization has declared mpox a global health emergency, and vaccine donations are being coordinated. The new strain has been confirmed in Sweden, and Pakistan is conducting sequencing to determine if it is the new strain. While the risk to the public in the US is considered low, healthcare providers are being advised to be vigilant.
Danish biotech firm Bavarian Nordic plans to increase production of its mpox vaccine to address the global health emergency declared by the WHO. The company will work with international health organizations to ensure fair access to the vaccine, particularly in Africa where the virus is spreading rapidly.
The eastern Congo, ravaged by conflict and displacement, is facing a silent threat from a new strain of mpox. With limited access to medical care and widespread unawareness of the disease, the outbreak poses a serious danger to the already vulnerable population.
Monkeypox, or mpox, a cousin of smallpox, has been declared a global health emergency by the World Health Organization (WHO) for the second time in two years. This resurgence is driven by a new, more virulent strain, raising concerns about its spread, particularly in India. This article explores the transmission, symptoms, prevention, and treatment of mpox, highlighting the importance of international cooperation and India’s preparedness for a potential outbreak.
China has announced mandatory screenings for mpox at its borders, following the World Health Organization’s declaration of a global health emergency. This comes as a new, more dangerous variant of mpox was detected in Sweden, raising concerns about its spread.
Danish drugmaker Bavarian Nordic announced its readiness to produce up to 10 million doses of its mpox vaccine by 2025 following the World Health Organization’s declaration of a global health emergency due to a surge in the virus in Africa. The company currently has 500,000 doses in stock and awaits orders from concerned countries before initiating production.
Sweden has confirmed its first case of Mpox caused by the Clade I variant, marking the first such case outside of the African continent. This comes a day after the World Health Organization (WHO) declared the increasing spread of Mpox in Africa a global health emergency.
